GrantSet

Special Notice · CBER-2026-133723

Notice of Intent to Sole Source: Vaccine Adverse Event Reporting System (VAERS) & Safety Monitoring Support

Responses due31h leftSep 18, 2026, 3:30 PM EDT
Buying agencyDepartment of Health and Human Services
Sub-tierFood and Drug Administration
OfficeFda Office of Acq Grant Svcs
NAICS541720 — Professional, Scientific, and Technical Services
PSCAJ11
Set-aside8(a) Business Development (Competed)
PostedSep 10, 2026
DeadlineSep 18, 2026, 3:30 PM EDT
Place of performanceCarmel, CA, 93923
From the notice

The Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER)�s Office of Biostatistics and Pharmacovigilance (OPBV)�s Division of Pharmacovigilance (DPV) is responsible for monitoring the safety of vaccines and biologics once they are approved for use under a Biologic Licensing Application (BLA) or authorized for use under an Emergency Use Authorization (EUA). The Contractor shall furnish the necessary services and qualified personnel needed to perform the Statement of Work.

Excerpt as published. The complete description, attachments, and any amendments are on the official notice.

View the official notice on SAM.gov ↗

GrantSet indexes public records and is not the official application channel. Responses and applications go through SAM.gov only — the official notice there controls if anything shown here differs.